Purpose: Conditionally Replicative Adenovirus (CRAd) has been previously demonstrated to augment the activity of radiation, resulting in synergy of cell kill. However, previous models combining radiation with CRAd have not focused on the methods of radiation delivery.
Materials And Methods: We model the combination of a novel prostate-specific CRAd, Ad5 PSE/PBN E1A-AR (Ad5: adenovirus 5; PSE: prostate-specific enhancer; PBN: rat probasin promoter; E1A: early region 1A; AR: androgen receptor), with radiation delivered both acutely and continuously, in an effort to better mimic the potential clinical modes of prostate cancer radiotherapy.
Results: We demonstrate that pre-treatment of cells with acute single high dose rate (HDR) radiation 24 hours prior to viral infection results in significantly enhanced viral replication and virus-mediated cell death. In addition, this combination causes increased level of gamma-H2AX (Phosphorylated histone protein H2AX on serine 139), a marker of double-stranded DNA damage and an indirect measure of nuclear fragmentation. In contrast, continuous low dose rate (LDR) radiation immediately following infection of the same CRAd results in no enhancement of viral replication, and only additive effects in virus-mediated cell death.
Conclusions: These data provide the first direct assessment of the real-time impact of radiation on viral replication and the first comparison of the effect of radiation delivery on the efficacy of CRAd virotherapy. Our data demonstrate substantial differences in CRAd efficacy based on the mode of radiation delivery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093921 | PMC |
| http://dx.doi.org/10.3109/09553000903419338 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Norepinephrine Use on Free Flap Survival in Breast Reconstructive Microsurgery.
Microsurgery
January 2025
Service de Chirurgie Plastique et Reconstructrice, Hôpital européen Georges-Pompidou, Paris, France.
Objective: The optimal method for maintaining intraoperative blood pressure during microsurgical procedures remains controversial. While intravenous fluid administration is essential, overfilling can lead to complications. Vasopressor agents are used cautiously due to their vasoconstrictive effects, which could potentially lead to flap failure.
View Article and Find Full Text PDFPredicting brain tumour growth patterns using a novel MRI-based tumour spread map: application to radiotherapy planning.
Med Phys
January 2025
Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, Canada.
Background: The treatment of glioblastomas (GBM) with radiation therapy is extremely challenging due to their invasive nature and high recurrence rate within normal brain tissue.
Purpose: In this work, we present a new metric called the tumour spread (TS) map, which utilizes diffusion tensor imaging (DTI) to predict the probable direction of tumour cells spread along fiber tracts. We hypothesized that the TS map could serve as a predictive tool for identifying patterns of likely recurrence in patients with GBM and, therefore, be used to modify the delivery of radiation treatment to pre-emptively target regions at high risk of tumour spread.
Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study).
BMC Cancer
January 2025
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background: Even though major improvements have been made in the treatment of myeloma, the majority of patients eventually relapse or progress. Patients with multiple myeloma who relapse after initial high-dose chemotherapy with autologous stem cells have a median progression free survival up to 2-3 years, depending on risk factors such as previous remission duration. In recent years, growing evidence has suggested that allogeneic stem cell transplantation could be a promising treatment option for patients with relapsed or progressed multiple myeloma.
View Article and Find Full Text PDFGalactic cosmic ray environment predictions for the NASA BioSentinel Mission, part 2:Post-mission validation.
Life Sci Space Res (Amst)
February 2025
NASA Ames Research Center, Moffett Field, CA 94035, United States.
The BioSentinel CubeSat was deployed on the Artemis-I mission in November 2022 and has been continuously transmitting physical measurements of the space radiation environment since that time. Just before mission launch, we published computational model predictions of the galactic cosmic ray exposure expected inside BioSentinel for multiple locations and configurations. The predictions utilized models for the ambient galactic cosmic ray environment, radiation physics and transport, and BioSentinel geometry.
View Article and Find Full Text PDFSpace radiation measured during first-ever commercial suborbital mission on Virgin Galactic SpaceShipTwo Unity on 29 June 2023.
Life Sci Space Res (Amst)
February 2025
National Research Council of Italy, Rome, Italy. Electronic address:
The paper presents the variations of space radiation (primary and secondary galactic cosmic rays (GCR) absorbed dose rate in silicon and flux) measured during the first-ever commercial suborbital flight of the Virgin Galactic (VG) SpaceShipTwo Unity on 29 June 2023. A Portable Dosimeter-Spectrometer Liulin-CNR-VG is used. It is developed in the Space Research and Technology Institute, Bulgarian Academy of Sciences (SRTI-BAS) under a scientific contract with National Research Council of Italy (CNR), Italy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!